Solutions
AlternativeSoft, a provider of buy-side analytics for manager research and portfolio construction in the alternatives and long only markets has announced AlternativeSoft v3.5.
With a reputation for consistently providing the latest academically proven quantitative models for fund analysis, AlternativeSoft has positioned itself at the forefront of fund analysis. The expansive platform provides users with comprehensive quantitative analytics, CRM functionality, bespoke reporting and fast user experience.
AlternativeSoft has announced it will be adding a full-suite of Private Equity fund analysis to its best-selling ‘Asset Selection’ and ‘Portfolio Construction’ modules which currently cover Hedge Funds, Long-only and ETFs. Developed in conjunction with
Waterland Private Equity has sold its stake in the Swiss nursing home operator SENIOcare to Swiss Prime Site AG, which is already active in the assisted living segment through its Tertianum group subsidiary.
The purchase price has not been disclosed.
Jörg Dreisow (pictured), Managing Partner of Waterland and responsible for the DACH region, says: "We have actively supported the successful business development of SENIOcare in the last three years and founded together with the company a strategic and financial basis for accelerated growth. The interest of a strategic investor with a complementary business model proves that SENIOcare is on
Audax Private Equity and Moelis Capital Partners (MCP) have completed the sale of Quest Construction Products (QCP) to Building Materials Corporation of America.
Upon closing, Audax and MCP will have fully exited their investments in Quest, following the sale of the Quest Automotive Products and Quest Industrial Products divisions to The Valspar Corporation earlier this year.
QCP manufactures and supplies roofing systems, coatings solutions, and protective pavement systems for the non-residential construction industry under the Hydro-Stop, United, and StreetBond brands. Since Audax’ and MCP’s initial investment in 2011, QCP completed two acquisitions, adding decorative asphalt coatings to its product
Arma Partners acted as exclusive financial advisor to JT Bioscopen, the second largest cinema chain in the Netherlands, and its selling shareholder on JT’s sale to Vue International.
JT operates 21 cinemas and 111 screens across the Netherlands. The Company is a leader in technical innovation in the global movie exhibitor sector. In December 2014, JT was the first exhibitor in the world to launch the cutting-edge Dolby Cinema format and, prior to this, was one of the first exhibitors to introduce laser projection and Dolby Atmos sound technology. The acquisition of JT reinforces Vue’s strategy to be at the
Keeley Asset Management is to transfer the voting shares of its parent company, Joley Corp (Joley), to TA Associates (TA).
In addition to TA's ownership, certain KAMCO employees will be participating with TA as non-controlling equity owners. The transfer is subject to the satisfaction of certain regulatory approvals and is expected to be completed in September 2015.
In July 2008, KAMCO completed a minority leveraged recapitalisation with TA, a leading global growth private equity firm with a strong track record of successful investments in the asset management industry.
"We were excited in 2008 to engage TA's proven asset management industry
Law firm Trowers & Hamlins advised international private equity firm C&C Alpha Group on the sale of Alpha Hospitals to Cygnet Health Care, one of the UK largest independent providers of mental health and social care pathways.
Alpha Hospitals operates three low to medium secure mental health facilities located in Bury, Woking and Sheffield. Since its initial investment in 2002, C&C Alpha Group has grown Alpha Hospitals substantially, developing highly specialised services and facilities that support men, women and adolescents with mental health conditions and learning disabilities.
The purchase will grow Cygnet Health Care's existing footprint from 17 mental
Fifteen years after the dotcom collapse we see another tech crash approaching. ‘Bubble’ and ‘unicorn’ are entering the mainstream vernacular. We are becoming comfortably numb with tech company overvaluations, says Victor Basta, managing partner at Magister Advisors…
The vocabulary has changed (for ‘dotcom’ read ‘unicorn’), the dynamics are different (largely private rather than public), but the impact on the tech sector, and the choices companies should be making now, are no less profound as the coming crash slowly unfolds.
The signs are already here that a serious correction is in the air:
• VC investment pace is blistering
Private equity firm GTCR has completed the previously announced sale of its portfolio company Cord Blood Registry (CBR) to AMAG Pharmaceuticals (AMAG), a specialty pharmaceutical company that focuses on maternal health and haematology, for USD700 million.
Founded in 1992, CBR is the world’s largest newborn stem cell company, entrusted by parents with storing over 600,000 stem cell samples. CBR is dedicated to supporting the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today. The Company provides services which enable expectant families to preserve
Inflexion has sold its Partnership Capital investment in Rhead Group (Rhead), a technical professional services consultancy, to Costain Group PLC (Costain) in a transaction valued at GBP36 million.
Acquisitive growth and diversification were the focus of our partnership. Inflexion supported four transformational add-on acquisitions broadening Rhead’s offering, customer base and strengthening both its national and overseas presence. During our partnership with Rhead, Inflexion worked closely with the management team introducing a highly experienced Chairman, as well as undertaking a digital audit to identify areas of improvement in systems and processes, aiding efficiency and assisting in the hire of a new
CXR Biosciences Limited, (CXR) the Dundee-based investigative and exploratory toxicology business, has been sold by its shareholders – including Archangel Investors and Scottish Investment Bank – to UK-based Concept Life Sciences, the growing life sciences, scientific laboratory and consultancy group.
CXR is a leading investigative toxicology business. Its in-house expertise assists international life sciences companies to resolve issues relating to the safety of compounds and with the selection of drug and chemical candidates. CXR, which has 33 staff, will retain its name and operate under the Concept Life Sciences’ Group umbrella. All staff, including the management team, are joining the Concept
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
